Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1

• US 8,951,981 B2
• Filed: 06/16/2010
• Issued: 02/10/2015
• Est. Priority Date: 06/16/2009
• Status: Active Grant

• Current Assignee: CURNA, Inc. (Opko Health, Inc.)
• Original Assignee: CURNA, Inc. (Opko Health, Inc.)
• Inventors: Collard, Joseph, Khorkova Sherman, Olga
• Primary Examiner(s): GIBBS, TERRA C
• Application Number:
  US13/377,884
• Publication Number:
  US 20120095081A1
• Time in Patent Office: 1,700 Days
• Field of Search: 514/44, 536/24.5
• US Class Current: 514/44.A
• CPC Class Codes: A61K 31/713 Double-stranded nucleic acids or oligonucleotides
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 15/08 for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/14 of the thyroid hormones, e.g. T3, T4
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 : Antihypertensives
• CPC Class Codes: C12N 15/1137 : against enzymes viral enzymes C12N15/1131; receptors C12N15/1138
• CPC Class Codes: C12N 2310/11 : Antisense
• CPC Class Codes: C12N 2310/113 : targeting other non-coding nucleic acids, e.g. antagomirs
• CPC Class Codes: C12N 2310/14 : interfering N.A.
• CPC Class Codes: C12Y 301/08001 : Aryldialkylphosphatase (3.1.8.1), i.e. paraoxonase

Abstract

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Paraoxonase 1(PON1), in particular, by targeting natural antisense polynucleotides of Paraoxonase 1(PON1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of PON1.

Claims

1. A method of upregulating a function of and/or the expression of a Paraoxonase 1 (PON1) polynucleotide having SEQ ID NO:

1 in patient cells or tissues in vivo or in vitro comprising;

contacting said cells or tissues with at least one single stranded antisense oligonucleotide 12 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 80% sequence identity to a reverse complement of a polynucleotide comprising 12 to 30 nucleotides within nucleotides 1 to 534 of SEQ ID NO;

2;

thereby upregulating a function of and/or the expression of the Paraoxonase 1 (PON1) polynucleotide in patient cells or tissues in vivo or in vitro.

12. The method of claim 1 wherein the at least one oligonucleotide comprises at least one oligonucleotide sequence set forth as SEQ ID NOS:

3.

2. A method of upregulating a function of and/or the expression of a Paraoxonase 1 (PON1) polynucleotide having SEQ ID NO:

1 in patient cells or tissues in vivo or in vitro comprising;

contacting said cells or tissues with at least one single stranded antisense oliganueleotide 12 to 30 nucleotides in length wherein said at least one oligonucleotide is specific for and specifically hybridizes to a natural antisense polynueleonde of the PON1 gene selected from SEQ ID NO;

2 and has at least 80% sequence identity to a reverse complement of said natural antisense of a Paraoxonase 1 (PON

     1) polynueleotide;

thereby upregulating a function of and/or the expression of the Paraoxonase 1 (PON1) polynueleotide in patient cells or tissues in vivo or in vitro.

3. A method of upregulating a function of and/or the expression of a Paraoxonase 1 (PON1) polynneleotide having SEQ ID NO:

1 in patient cells or tissues in vivo or in vitro comprising;

contacting said cells or tissues with at least one single stranded antisense oligonueleotide 12 to 30 nucleotides in length wherein said oligonucleotide is specific for a natural antisense polynueicotide having SEQ ID NO;

2 and has at least 90% sequence identity to an RNA polynueleotide transcribed from the Paraoxonase 1 (PON1) polynucleotide;

thereby upregulating a function of and/or the expression of the Paraoxonase 1 (PON1) polynucleotide in patient cells or tissues in vivo or in vitro.

4. A method of upregulating a function of and/or the expression of a Paraoxonase 1 (PON1) polynueleotide having,SEQ ID NO:

1 in patient cells or tissues in vivo or in vitro comprising;

contacting said cells or tissues with at least one modified single stranded antisense oligonucleotide of 12 to 30 nucleotides in length that targets a region of a natural antisense polynucleotide of the Paraoxonase 1 (PON1) polynueleotide having SEQ ID NO;

2;

thereby upregulating a function of and/or the expression of the Paraoxonase 1 (PON1) polynucleotide in patient cells or tissues in vivo or in vitro.

5. The method of claim 4, wherein a function of and/or the expression of the Paraoxonase 1 PON1) is increased in vivo or in vitro with respect to a control.

6. The method of claim 4, wherein the at least one antisense oligonucleotide targets a natural antisense polynucleotide antisense to coding and/or non-coding nucleic acid sequences of a Paraoxonase 1 (PON1) polynucleotide.

7. The method of claim 4, wherein the at least one antisense oligonucleotide targets a natural antisense polynucleotide having overlapping and/or non-overlapping sequences with a Paraoxonase 1 (PON1) polynucleotide.

8. The method of claim 4, wherein the at least one antisense oligonueleotide comprises one or more modifications selected from:

at least one modified sugar moiety, at least one modified internueleoside linkage, at least one modified nucleotide., and combinations thereof.

9. The method of claim 8, wherein the one or more modifications comprise at least one modified sugar moiety selected from;

a 2′

-O-methoxyethyl modified sugar moiety, a 2′

-methoxy modified sugar moiety, a 2′

-O-alkyl modified sugar moiety, a bicyclic sugar moiety, and combinations thereof.

10. The method of claim 8, wherein the one or more modifications comprise at least one modified .interaueleoside linkage selected from:

a phosphorothioate, alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carhoxymethyl ester, and combinations thereof.

11. The method of claim 8, wherein the one or more modifications comprise at least one modified nucleotide selected from:

a peptide nucleic acid (PNA), a locked nucleic acid (LNA), an arabino-nucleic acid (FANA), an analogue, a derivative, and combinations thereof.

13. A method of upregulating a function of and/or the expression of a Paraoxonase 1 (PON1) gene in mammalian cells or tissues in vivo or in vitro comprising:

contacting said cells or tissues with at least one short interfering RNA (siRNA) oligonucleotide 19 to 30 nucleotides in length, said at least one siRNA oligonucleotide being specific for a natural antisense polynucleotide of a Paraoxonase 1 (PON1) polynucleotide, wherein said at least one siRNA oligotateleotide has at least 80% sequence identity to at least about 19 consecutive nucleic acids of the RNA sense nucleic acid molecule transcribed from the Paraoxonase 1 (PON1) polynticleotide; and

, upregulating a function of and/or the expression of Paraoxonase 1 (PON1) in mammalian cells or tissues in vivo or in vitro.

14. The method of claim 13, wherein said oligonucleotide has at least 90% sequence identity to a sequence of at least about 19 consecutive nucleic acids of said RNA sense nucleic acid molecule transcribed from the Paraoxonase 1 (PON1) polynucleotide.

15. A method of upregulating a function of and/or the expression of Paraoxonase 1 (PON1) having SEQ ID NO:

1 in mammalian cells or tissues in vivo or in vitro comprising;

contacting said cells or tissues with at least one modified single stranded antisense oligonucleotide of about 12 to 30 nucleotides in length specific for noncoding and/or coding sequences of a natural antisense strand of a Paraoxonase 1 (PON1) polynucleotide wherein said at least one antisense oligonucleotide has at least 90% sequence identity to at least one nucleic acid sequence of 12 to 30 nucleotides in length set forth within SEQ ID NO;

1 or an RNA transcribed from the PON1polynucleotide; and

, upregulating the function and/or expression of the Paraoxonase 1(PON1) in mammalian cells or tissues in vivo or in vitro.

16. A method of preventing or treating a disease associated with at least one Paraoxonase 1 (PON1) polynucleotide and/or at least one encoded product thereof, comprising:

administering to a patient a therapeutically effective dose of at least one single stranded antisense oligonucleotide of 12 to 30 nucleotides in length that specifically binds to a natural antisense sequence of said at least one Paraoxonase 1 (PON1) polynucleotide and upregulates expression of said at least one Paraoxonase 1 (PON1) polynucleotide;

thereby preventing or treating the disease associated with the at least one Paraoxonase 1 (PON1) polynucleotide and/or at least one encoded product thereof wherein said disease or disorder is selected from atherosclerosis, hypercholesterolemia or induced stress due to exogenous compounds.

17. The method of claim 16, wherein a disease associated with the at least one Paraoxonase 1 (PON1) polynucleotide is selected from;

atherosclerosis, stress induced by exposure to various exogenous compounds such as environmental chemicals selected from metals such as, cobalt, cadmium, nickel, zinc, copper, barium, lanthanum, mercurials;

diehloroacetic acid, carbon tetrachloride, drugs selected from cholinergic muscarinic antagonist, pravastatin, simvastatin, fluvastatin, alcohol.